atezolizumab
Start here
A Jackson Laboratory team publishing in Science used long-read RNA sequencing to identify thousands of previously unrecognized STAT2 splicing variants in lung cancer. Intron-retaining STAT2 was associated with longer survival on the anti-PD-L1 drug atezolizumab, validated with data from two large clinical trials. The splicing signature could potentially identify patients likely to benefit from immunotherapy, and the team has filed a provisional patent for correcting splicing errors and predicting response (DOI: 10.1126/science.aea7156).
Excerpted from medicalxpress.com
Coverage timeline
Follow the coverage to see the different angles.
- medicalxpress.comPickOverlooked 'off switch' in lung tumors may explain why immunotherapy doesn't work for everyone
A Jackson Laboratory team publishing in Science used long-read RNA sequencing to identify thousands of previously unrecognized STAT2 splicing variants in lung cancer. Intron-retaining STAT2 was associated with longer survival on the anti-PD-L1 drug atezolizumab, validated with data from two large clinical trials. The splicing signature could potentially identify patients likely to benefit from immunotherapy, and the team has filed a provisional patent for correcting splicing errors and predicting response (DOI: 10.1126/science.aea7156).
Heat trend for this story
Heat now 15·Peak in the comparable set 17 (Oct 26 05:00)·Change over 24h in the comparable set +20%·Participants now 3
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.